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Fibroblast growth factor receptor 4 (FGFR4): a
targetable regulator of drug resistance in colorectal
cancer
RC Turkington1, DB Longley1, WL Allen1, L Stevenson1, K McLaughlin1, PD Dunne1, JK Blayney2, M Salto-Tellez3,
S Van Schaeybroeck1 and PG Johnston*,1
The discovery of underlying mechanisms of drug resistance, and the development of novel agents to target these pathways, is a
priority for patients with advanced colorectal cancer (CRC). We previously undertook a systems biology approach to design a
functional genomic screen and identified fibroblast growth factor receptor 4 (FGFR4) as a potential mediator of drug resistance.
The aim of this study was to examine the role of FGFR4 in drug resistance using RNAi and the small-molecule inhibitor BGJ398
(Novartis). We found that FGFR4 is highly expressed at the RNA and protein levels in colon cancer tumour tissue compared with
normal colonic mucosa and other tumours. Silencing of FGFR4 reduced cell viability in a panel of colon cancer cell lines and
increased caspase-dependent apoptosis. A synergistic interaction was also observed between FGFR4 silencing and
5-fluorouracil (5-FU) and oxaliplatin chemotherapy in colon cancer cell lines. Mechanistically, FGFR4 silencing decreased
activity of the pro-survival STAT3 transcription factor and expression of the anti-apoptotic protein c-FLIP. Furthermore, silencing
of STAT3 resulted in downregulation of c-FLIP protein expression, suggesting that FGFR4 may regulate c-FLIP expression via
STAT3. A similar phenotype and downstream pathway changes were observed following FGFR4 silencing in cell lines resistant
to 5-FU, oxaliplatin and SN38 and upon exposure of parental cells to the FGFR small-molecule inhibitor BGJ398. Our results
indicate that FGFR4 is a targetable regulator of chemo-resistance in CRC, and hence inhibiting FGFR4 in combination with 5-FU
and oxaliplatin is a potential therapeutic strategy for this disease.
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Colorectal cancer (CRC) is the second commonest cause of
cancer-related deaths in theWesternWorld, and resistance to
chemotherapy remains the primary reason for treatment
failure in advanced CRC.1 The exposure of increasing
numbers of metastatic CRC patients to oxaliplatin, as well
as its introduction into the adjuvant therapy of early stage
CRC, has led to efforts to identify and target mechanisms of
drug resistance to oxaliplatin. In a previous study, we used a
systems biology approach to reveal novel genes and path-
ways mediating drug resistance to 5-fluorouracil (5-FU) and
oxaliplatin in CRC and identified fibroblast growth factor
receptor 4 (FGFR4) as a potential druggable mediator of
chemo-resistance.2
FGFR4 is one of a family of highly conserved tyrosine
kinase receptors that regulate cellular pathways involved in
proliferation, differentiation and survival.3 Four of the recep-
tors (FGFR1–4) possess tyrosine kinase domains and are
activated by the binding of one of 18 secreted glycoprotein
FGFs to their extracellular immunoglobulin domains (Ig I–III).4
Ligand binding results in FGFR dimerisation, auto-phosphor-
ylation of the intracellular split tyrosine kinase domain and
activation of downstream signalling pathways, such as the
Ras-dependent mitogen-activated protein kinase (MAPK)
pathway, AKT-dependent anti-apoptotic pathway and signal
transducer and activator of transcription (STAT) signalling.3,5
FGFR4 is expressed as a single FGFR4-IIIc isoform resulting
in increased selectivity in relation to its FGF binding partners
such that, in the absence of the single transmembrane
containing co-factor b-Klotho, only FGF19 can bind to FGFR4
and initiate its downstream signal transduction pathways.4,6,7
FGFR4 has been found to be of importance in a number of
tumour types, with overexpression occurring in prostate,
breast, pancreatic, pituitary, hepatocellular and gynaecologi-
cal tumours.8–16 Initial observations of an increased rate of
hepatocellular carcinoma formation in FGF19 transgenic mice
and the predominant expression of FGFR4 in the liver
provided a link between FGF19-FGFR4 signalling and
tumourigenesis.11,17,18 Recently, FGFR4 has been recognised
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as an oncogene in breast cancer cell lines and activating
mutations occur in up to 7% of rhabdomyosarcoma (RMS)
tumours during tumourigenesis.19,20 In other tumour types,
FGFR4 mutations are infrequent, but the single-nucleotide
polymorphism FGFR4 G388R increases stability, prolongs
activation of the receptor, and is associated with a poor
prognosis in melanoma, breast, prostate and head and neck
cancers.21–24 In colon cancer, FGFR4 has an important role in
tumour–stroma interaction and the presence of the FGFR4
G388R substitution correlates significantly with advanced
tumour stage and lymph node metastases.21,25 Inhibition of
FGF19-FGFR4 signalling in colon cancer using an FGF19
blocking antibody (IA6) has been shown to disrupt FGF19
binding to FGFR4, inhibiting the growth of HCT116 and
Colo201 xenograft tumours.26 In relation to chemo-resis-
tance, a role for FGFR4 has recently been described, with
upregulation of FGFR4 in response to the DNA-damaging
agent Doxorubicin.27
Considering the role of FGFR4 in resistance to DNA-
damaging agents and the efficacy of disrupting FGF19-
FGFR4 signalling in colon cancer, both in vitro and in vivo,
we hypothesised that inhibition of FGFR4 represents a novel
strategy for overcoming drug resistance in CRC. In this study,
we demonstrate that silencing of FGFR4 induces caspase-
dependent apoptosis in a panel of parental and drug-resistant
colon cancer cell lines. Mechanistically, we discovered a role
for FGFR4 as a regulator of signal transducer and activator of
transcription 3 (STAT3) activity and apoptosis via its regula-
tion of the anti-apoptotic proteins cellular FLICE-inhibitory
protein (c-FLIP) and B-cell lymphoma-2 (Bcl-2). Our results
indicate the influential role played by FGFR4 in CRC and the
potential importance of targeting this receptor as a strategy to
overcome drug resistance.
Results
Altered FGF expression in parental and drug-resistant
CRC models. Transcriptional profiling of parental, 5-FU-
and oxaliplatin-resistant HCT116 cells was carried out as
previously described.2 Analysis of the microarray data
revealed that gene expression of a number of FGFR ligands
was acutely altered in response to chemotherapy treatment
or constitutively altered in the 5-FU- or oxaliplatin-resistant
cells (Supplementary Table 1). Of note, only FGFR4 is
capable of binding all of the ligands significantly altered in our
data set. We next evaluated pharmacological blockade of
FGFR signalling using BGJ398 (Novartis, Basel, Switzerland),
a small-molecule inhibitor of FGFR1-4 (in vitro kinase assay
IC50 values of 0.9, 1.4, 1 and 60 nM for FGFR1–4,
respectively).28 BGJ398 inhibited cell viability in a dose-
dependent manner in HCT116, HKH2, RKO and LS174T
colon cancer cells with IC50 doses in the low micromolar
range (Figure 1a) and significant increases in apoptosis were
observed in HCT116 cells treated with BGJ398 in combina-
tion with 5-FU or oxaliplatin (Po0.001 and Po0.01,
respectively) (Figure 1b). We subsequently included
FGFR1-4 in a functional genomic small interfering RNA
(siRNA) screen and identified FGFR4 (but not FGFR1,
FGFR2 or FGFR3) as a potential mediator of chemo-
resistance (Figure 1c). Inhibition of FGFR4 activity
(as monitored by its phosphorylation status) following stimula-
tion with FGF19 and BGJ398 treatment was confirmed at an
IC50 dose (Figure 1d). Taken together, these results indicate
that disruption of FGFR signalling occurs in response to
chemotherapy treatment and that inhibition of FGFR4 activity
sensitises colon cancer cells to chemotherapy.
FGFR4 is differentially expressed in human colon
adenocarcinoma versus normal colonic mucosal tissue.
Analysis of the Oncomine database of publically available
microarray expression data revealed upregulation of FGFR4
mRNA in CRC compared with normal colon tissues and in
relation to other cancers (Figure 2a). FGFR2 mRNA was
found to be upregulated in CRC compared with normal colon
in a single data set, but no significant differences were found
for FGFR1 or FGFR3 (data not shown). Having demon-
strated an increase in FGFR4 expression at the mRNA level,
we sought to examine FGFR4 expression in tumour tissue.
Using a tissue microarray (TMA) compiled from 149 early
stage CRC patients (Supplementary Table S2), we investi-
gated the expression of FGFR4 in matched tumour and
adjacent normal tissues using an antibody to the C-terminus
portion of the receptor. Analysis of staining in the normal
colonic epithelium showed predominant absence or mild
staining (Figure 2b, upper panel). In addition, significantly
higher nuclear staining was observed in the tumour tissue
compared with normal colon (P¼ 1.679e-14) (Figure 2b,
lower panel). Considering this data and the previous results
from the siRNA-mediated and pharmacological inhibition of
FGFR4, we selected FGFR4 for further functional analysis as
a novel and potentially druggable target in CRC.2
FGFR4 silencing synergistically enhances the effects of
chemotherapy in a panel of colon cancer cells. HCT116
cells were transfected for 48 h with 1–5 nM siRNA targeting
FGFR4 (siFGFR4), and silencing was confirmed by western
blotting (Figure 3a). Quantitative-PCR analysis showed that
silencing of FGFR4 did not significantly affect the expression
of FGFR1-3 in HCT116 and RKO cells at the 24 or 48 h
timepoints (Supplementary Figure S1A). In order to examine
the effects of FGFR4 silencing in a range of genetic
backgrounds, we utilised a panel of colon cancer cell lines
displaying mutations in KRAS (HCT116, LS174T), BRAF
(RKO) and PIK3CA (HCT116, HKH2, LS174T, RKO).
HCT116, HKH2 and RKO cells were transfected for 24 h
with siFGFR4 before a 24/48 h co-treatment with a range of
doses of 5-FU/oxaliplatin. Combination Index (CI) values
were calculated and indicated that FGFR4 silencing syner-
gised with 5-FU and oxaliplatin treatment in HCT116, HKH2
and RKO cell line models, particularly at low drug concentra-
tions (Figure 3b). Similar results were obtained using two
further FGFR4 siRNA sequences (Supplementary Figures
S1B and C).
To examine the mechanism of synergy between FGFR4
siRNA and chemotherapy, apoptosis was assessed. PARP
(poly-ADP ribose polymerase-1) cleavage was induced by
FGFR4 silencing alone, and this was further increased in the
presence of chemotherapy (Figure 3c). In HCT116 cells,
FGFR4 silencing resulted in significantly higher levels of
apoptosis compared with cells transfected with the negative
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control siRNA (Po0.05; Figure 3d). In the presence of
chemotherapy treatment, apoptosis in FGFR4-silenced cells
was further enhanced for both 5-FU and oxaliplatin (Po0.001
and Po0.01, respectively), with a synergistic interaction
between 5-FU and siFGFR4 confirmed using two-way
ANOVA (P¼ 0.0275). In the HKH2 cell line, the addition of
siFGFR4 to 5-FU or oxaliplatin significantly increased
apoptosis for both drugs (Po0.001), and the interaction was
synergistic (P¼ 0.0208 and 0.0028 for 5-FU and oxaliplatin,
respectively). Similar results were observed in the RKO and
LS174T cell lines (Figure 3d) and with the use of two further
FGFR4 siRNA sequences (Supplementary Figure S1D).
These results demonstrate that FGFR4 silencing reduces
cell viability, induces apoptosis and enhances the apoptotic
effects of both 5-FU and oxaliplatin. Moreover, these effects
are not dependent on the mutational status of the KRAS
oncogene as indicated by the results from HCT116 and HKH2
KRAS mutant and wild-type paired cell lines.
FGFR4 silencing induces caspase-dependent apoptosis
in colon cancer cell lines. Caspase-dependent apoptosis
following FGFR4 silencing was assessed using the pan-
caspase inhibitor zVAD, which completely attenuated apop-
tosis (Figure 4a). Moreover, activity of the executioner
caspases 3 and 7 was significantly induced following
transfection of HCT116 and HKH2 cells with siFGFR4
(Figure 4b and data not shown). IC30 (48 h) doses of 5-FU or
oxaliplatin failed to significantly increase caspase 3/7 activity
but did further increase caspase 3/7 activity when FGFR4
was silenced in the HCT116 and HKH2 cell lines (Figure 4b
and data not shown). To define the relative importance of the
extrinsic and intrinsic apoptotic pathways in mediating
siFGFR4-induced apoptosis, we used siRNAs targeting
caspase 8 (extrinsic pathway) or caspase 9 (intrinsic path-
way). Notably, silencing of either caspase prevented
apoptosis induced by FGFR silencing (Figure 4c). In addition,
transfection of Bax null HCT116 cells with siFGFR4 failed to
induce PARP cleavage, confirming the role of the intrinsic
apoptotic pathway in siFGFR4-induced apoptosis
(Figure 4d). Together, these results suggest that siFGFR4-
induced apoptosis proceeds via caspase 8-mediated activa-
tion of the Bax-regulated, caspase 9-dependent intrinsic
apoptotic pathway, consistent with HCT116 cells being type
II with respect to the extrinsic pathway.29
FGFR4 silencing downregulates the anti-apoptotic pro-
teins c-FLIP and Bcl-2 and reduces STAT3 activity in
colon cancer cells. To further study the mechanism of
apoptosis in HCT116 cells, the expression levels of pro- and
anti-apoptotic proteins were assessed following transfection
Figure 1 Small-molecule inhibition of the FGFRs inhibits cell growth and induces apoptosis. (a) MTT cell viability assays of HCT116, HKH2, RKO and LS174T cells treated
for 48 h with increasing concentrations of BGJ398. Absorbance was measured at 570 nM. (b) Annexin V/PI flow cytometric analysis was used to measure the levels of
apoptosis in the HCT116 cell line following treatment with IC30 (48 h) doses of 5-FU or oxaliplatin for 48 h and co-treatment with IC30 (48 h) doses of BGJ398 for a further 24 h.
Significance was determined by two-way analysis of variance. Results are presented as mean values±S.E.M. for three replicate experiments (**Po0.01, ***Po0.001).
(c) MTT cell viability assay results showing percentage of surviving HCT116 cells transfected for 24 h with siFGFR1, siFGFR2, siFGFR3 or siFGFR4 before treatment with
solvent control or IC30 (48 h) doses of 5-FU or oxaliplatin. (d) Immunoprecipitation using a phospho-tyrosine antibody was performed on HCT116 cells pre-treated with an IC50 (48 h)
dose of BGJ398 for 24 h followed by a further IC50 (48 h) dose of BGJ398±100 ng/ml of FGF19 before immunoblotting for FGFR4
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Figure 2 FGFR4 is differentially expressed in human colon adenocarcinoma versus normal colonic mucosal tissue. (a) FGFR4 transcriptional profiling in the Oncomine
database. The Oncomine database of publicly available microarray data was searched for differential expression of FGFR4 between normal colon and colonic
adenocarcinoma tissue. The bar graphs and box plots are shown for each data set as well as the sample breakdown, reference, platform used, fold change and level of
significance as determined by the Student’s t-test. (b) Representative high-powered ( 40) images illustrating weak nuclear staining for FGFR4 in normal colon and strong
nuclear staining in colonic adenocarcinomas. Bar graph representing the relative immunoreactivity score calculated for FGFR4 nuclear staining in normal and malignant
colorectal epithelial cells
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Figure 3 FGFR4 silencing synergistically enhances the effects of chemotherapy in a panel of colon cancer cells. (a) Transfection of HCT116 cells was carried out using
1–5 nM of siFGFR4, and FGFR4 silencing was confirmed by western blotting. The unmodified receptor is present at 88 kDa while the phosphorylated and glycosylated forms
are present at 88–125 kDa. (b) Cell viability assays were conducted in the HCT116, HKH2 and RKO cell lines using a MTT assay following FGFR4 silencing (siFGFR4 1–5 nM)
for 24 h before co-treatment with parental IC30 (48 h) and IC50 (48 h) doses of chemotherapy for 24/48 h. The method of Chou and Talalay was used to evaluate the interaction
between siFGFR4 and either 5-FU or oxaliplatin at 48 or 72 h. CI values were calculated using Calcusyn v2.0 where valueso1,¼ 1 and41 indicate synergism, additivity and
antagonism, respectively. (c) HCT116 cells were transfected with negative control siRNA or siFGFR4 for 24 h before a 48 h co-treatment with IC30 (48 h) doses of either 5-FU or
oxaliplatin. Western blotting was performed for PARP cleavage with equal loading assessed by probing for GAPDH. (d) Apoptosis was assessed using Annexin V/PI flow
cytometric analysis. HCT116, HKH2 and RKO cells were transfected with 5 nM siFGFR4 and LS174T cells with 10 nM siFGFR4 for 24 h before a 48 h co-treatment with IC30 (48 h)
doses of either 5-FU or oxaliplatin. Percentage of cells in early apoptosis (Annexin V positive/PI negative, bottom right quadrant) and late apoptosis (Annexin V positive/PI
positive, upper right quadrant) are indicated. Significance and synergism were determined by two-way analysis of variance. Results are presented as mean values±S.E.M.
for three replicate experiments (*Po0.05, **Po0.01, ***Po0.001)
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with siFGFR4 for 24–72 h. In keeping with our previous data,
FGFR4 silencing induced PARP cleavage, processing of
procaspase 8 and downregulation of the anti-apoptotic
proteins Bcl-2 and both the long and short splice forms of
c-FLIP compared with time-matched controls (Figure 5a).
No significant changes were noted in the expression of other
apoptosis-regulating proteins. Analysis of mRNA expression
confirmed reduction of c-FLIP mRNA expression following
transfection with siFGFR4, and a reduction in Bcl-2 expres-
sion was also observed at 48 h (Figure 5b). A similar
decrease in c-FLIP and Bcl-2 expression was observed in
the RKO cell line (Supplementary Figure S2A). Given the role
of caspase 8 in siFGFR4-induced apoptosis and the down-
regulation of the endogenous inhibitor of caspase 8, c-FLIP,
we next examined the effect of FGFR4 silencing in the
c-FLIPL overexpressing cell line FL17.
30 Flow cytometric
analysis demonstrated that the FL17 cell line was signifi-
cantly more resistant to siFGFR4-induced apoptosis com-
pared with the parental HCT116 cell line (Po0.001,
Figure 5c).
To assess changes in pro-survival signal transduction
pathways induced by FGFR4 silencing that may be affecting
c-FLIP and Bcl-2 expression, HCT116, RKO and LS174T
cells were transfected with siFGFR4 for 24–48 h. Most
notably, STAT3 activation as assessed by Y705 phospho-
rylation was reduced after 24 and 48 h following transfection
in each of these cell lines (Figure 5d). These results
were confirmed using other FGFR-targeting siRNAs
(Supplementary Figure S2B) and BGJ398 (Supplementary
Figure S2C). A STAT3-driven luciferase reporter gene
Figure 4 FGFR4 silencing induces caspase-dependent apoptosis in colon cancer cell lines. (a) Annexin V/PI flow cytometric analysis was used to measure levels of
apoptosis following transfection with siFGFR4 for 24 h before co-treatment with an IC30 (48 h) doses of either 5-FU or oxaliplatin±10mM zVAD. (b) Caspase 3/7 activity levels
were measured in HCT116 cells following 24–72 h FGFR4 silencing alone (5 nM siFGFR4) or co-treatment for 24 h with IC30 (48 h) doses of 5-FU or oxaliplatin following 24 h
FGFR4 silencing. (c) Western blotting was used to measure the expression of FGFR4, PARP, Pro-Caspase 8 and Caspase 9 following transfection with either 20 nM
siCaspase 8 or 10 nM siCaspase 9 for 24 h followed by transfection with 5 nM siFGFR4 or 5 nM siRNA negative control and harvested after a further 24 h. (d) Western blotting
showing the effects of FGFR4 silencing at 24 and 48 h in Bax null HCT116 cells by probing for expression of FGFR4 and PARP. Equal loading was assessed by probing for
GAPDH or actin. Significance and synergism were determined by two-way analysis of variance (a) or Student’s t-test (b). Results are presented as mean values±S.E.M. for
three replicate experiments (*Po0.05, **Po0.01, ***Po0.001)
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Figure 5 FGFR4 silencing downregulates the anti-apoptotic proteins c-FLIP and Bcl-2 and reduces pSTAT3 activity in colon cancer cells. (a) Western blotting was used to
measure expression of FGFR4, PARP, Pro-Caspase 8, Caspase 8 p18, FLIPL, FLIPS, Bcl-2, BCLXL, Bax, MCL1 and XIAP at 24–72 h following transfection with 5 nM
siFGFR4. (b) Q-PCR of c-FLIP and Bcl-2 expression following transfection of HCT116 cells with siFGFR4 for 24–48 h. (c) Annexin V/PI flow cytometric analysis was used to
measure apoptosis in HCT116 parental cells and the overexpressing cell line, FL17, following 72 h FGFR4 silencing. (d) Western blotting was used to measure expression of
FGFR4, pSTAT3, tSTAT3, pAKT, tAKT, pERK and tERK following transfection of 5 nM siFGFR4 for 24–48 h in HCT116, 48 h in RKO and 10 nM siFGFR4 for 48 h in LS174T
cells. (e) A luciferase construct STAT3 reporter assay was used to measure STAT3 activity in HCT116 at 24 and 48 h following transfection with 5 nM siFGFR4. (f) Western
blotting was used to measure the expression of pSTAT3, tSTAT3, c-FLIPL and Bcl-2. Equal loading was assessed by probing for GAPDH or actin. Significance was assessed
by two-way analysis of variance (c) or Student’s t-test (b and d). Results are presented as mean values±S.E.M. for three replicate experiments (*Po0.05, **Po0.01,
***Po0.001)
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confirmed a significant reduction in STAT3 activity 48 h after
transfection with siFGFR4 (Po0.01) (Figure 5e). Further-
more, silencing of STAT3 in HCT116 cells resulted in
downregulation of c-FLIP protein expression although expres-
sion of Bcl-2 was unaffected (Figure 5f), suggesting that
FGFR4 may regulate FLIP, but not Bcl-2, expression via
STAT3.
FGFR4 silencing induces apoptosis in drug-resistant
colon cancer cell lines. To assess the effects of FGFR4
silencing in the context of acquired drug resistance,
previously described drug-resistant HCT116 models were
used.31 CI values were calculated following transfection with
1–10nM siFGFR4 before 24/48 h co-treatment with a range
of doses of 5-FU, oxaliplatin or SN38 (the active metabolite of
irinotecan) (Figure 6a). Silencing of FGFR4 interacted
synergistically with the chemotherapeutic agent to which
the cells were resistant and a second agent. Basal
expression of FGFR4 in these resistant cell lines was similar
to the parental cell line (Supplementary Figure S3).
A significant reduction in cell viability was observed in the
HCT116 5-FU- (HCT116 FUR), oxaliplatin- (HCT116 OXR)
and SN38-resistant (HCT116 SNR) cells following FGFR4
silencing alone or in combination with IC30 (48 h) chemother-
apy (Figure 6b). Markedly elevated levels of apoptosis were
observed following silencing of FGFR4 in all three drug-
resistant models (Figure 6c compared to Figure 3d). The
oxaliplatin- and SN38-resistant models were more sensitive
to loss of FGFR4 than the parental cells, as assessed by flow
cytometric measurement of apoptosis (Figure 6d), indicating
addiction of these drug-resistant cells to FGFR4 signalling.
Similar to the parental cells, activation of caspase 3/7 was
observed following transfection with siFGFR4 in both the
HCT116 FUR and OXR cell lines (Figure 6e); this was
accompanied by downregulation of c-FLIPL, c-FLIPS and
pSTAT3 (Y705) (Figure 6f). In addition, processing of caspase 8
to its active p18-form was observed after 48 h following
transfection of the HCT116 FUR and OXR cell lines with
FGFR4 siRNA; this was particularly apparent in the OXR cell
line (Figure 6f). However, no changes in Bcl-2 were observed
following FGFR4 silencing in these drug-resistant cell lines.
Discussion
Despite significant developments in conventional chemo-
therapy and targeted agents over the past two decades,
overall survival for patients with metastatic CRC remains
poor.32 The effectiveness of current chemotherapeutic agents
is limited by drug resistance, thus the discovery of the
mechanisms governing the cellular response to chemother-
apy is a priority.33 This study provides evidence of FGFR4 as
a novel determinant of chemo-resistance and its potential as a
drug target in CRC.
Recently, a role for FGFR4 has been described in the
resistance of breast cancer cells to the DNA-damaging agents
doxorubicin and cyclophosphamide.27 Upregulation of
FGFR4 was found in a doxorubicin-resistant MDA-MB-453
breast cancer cells, and silencing of FGFR4 significantly
increased apoptosis. FGFR4 was highly expressed in our
tumour CRC TMA, and we demonstrate for the first time that
FGFR4 has an important role in resistance to oxaliplatin and
5-FU treatment in a range of CRC cell line models.
Furthermore, silencing of FGFR4 in combination with che-
motherapy was not only capable of inducing a significant
increase in apoptosis in parental cell lines but also in 5-FU-,
oxaliplatin- and SN38-resistant cell lines. In fact, the oxalipla-
tin-resistant cell line and a cell line resistant to SN38 (the
active metabolite of irinotecan) weremore sensitive to FGFR4
depletion than the parental cell line, suggesting increased
dependence on FGFR4 in the setting of acquired drug
resistance.
FGFR4 acts through a number of pathways via intracellular
molecules, such as FGFR substrate 2a (FRS2a), phospholi-
pase C (PLCg) and STAT3.34–37 Inhibition of FGFR4 in breast
and RMS cell lines has been shown to downregulate ERK
activity, indicating a role for MAPK pathway inhibition in the
induction of apoptosis following FGFR4 blockade in these
models.27,38 However, we did not observe consistent changes
in ERK or Akt activation in response to FGFR4 silencing,
whereas changes in STAT3 activity were consistently
observed. FGFR4, along with FGFR1 and FGFR3, has been
shown to modulate the activity of STAT3, and in pituitary
tumours the polymorphic FGFR4 G388R variant mediates
pituitary oncogenesis through activation of STAT3, but not the
MAPK pathway.37,39 Further downstream of FGFR4, we
found that expression of the anti-apoptotic proteins Bcl-2,
c-FLIPL and c-FLIPS were downregulated in response to
FGFR downregulation. Moreover, c-FLIP expression was
both FGFR4- and STAT3-dependent, suggesting that FGFR4
regulates c-FLIP expression via STAT3. In contrast, Bcl-2
expression was not STAT3-dependent, indicating that FGFR4
regulates its expression via an alternative mechanism. In
drug-resistant cell lines, FGFR4 silencing also downregulated
c-FLIP expression, although Bcl-2 expression was unaltered.
Figure 6 FGFR4 silencing induces apoptosis in drug-resistant colon cancer cell lines. (a) Cell viability assays were conducted in the HCT116 parental, 5-FU-, oxaliplatin-
and SN38-resistant cell lines using a MTT assay following FGFR4 silencing (siFGFR4 1–10 nM) for 24 h before co-treatment with parental IC30 (48 h) and IC50 (48 h) doses of
chemotherapy for 24/48 h. The method of Chou and Talalay was used to evaluate the interaction between siFGFR4 and either 5-FU oxaliplatin or SN38 at 48 or 72 h. CI values
were calculated using Calcusyn v2.0 where valueso1,¼ 1 and41 indicate synergism, additivity and antagonism, respectively. (b) Cell viability of HCT116 parental, 5-FU-,
oxaliplatin- and SN38-resistant cell lines (HCT116 FUR, OXR and SNR, respectively) was assessed using a MTT assay following FGFR4 silencing (siFGFR4 10 nM for
resistant lines) for 24 h before co-treatment with parental IC30 (48 h) and IC50 (48 h) doses of chemotherapy. (c) Apoptosis was assessed using Annexin V/PI flow cytometric
analysis. HCT116 FUR, OXR and SNR cells were transfected with 10 nM siFGFR4 for 24 h before a 48-h co-treatment with IC30 (48 h) parental cell line doses of either 5-FU,
oxaliplatin or SN38. Percentage of cells in early apoptosis (Annexin V positive/PI negative, bottom right quadrant) and late apoptosis (Annexin V positive/PI positive, upper
right quadrant) are indicated. Significance and synergism were determined by two-way analysis of variance. Results are presented as mean values±S.E.M. for three replicate
experiments (*Po0.05, **Po0.01, ***Po0.001). (d) Apoptosis was assessed using Annexin V/PI flow cytometric analysis following transfection of HCT116 parental and
drug-resistant cell lines with siFGFR4 according to the conditions previously described. (e) Caspase 3/7 activity levels were measured in HCT116 FUR and OXR cells following
24–72 h FGFR4 silencing (10 nM siFGFR4). (f) Western blotting was used to measure expression of FGFR4, pSTAT3, tSTAT3, Pro-Caspase 8, Caspase 8 p18, FLIPL, FLIPS
and BCL2 at 24 and 48 h following transfection with 10 nM siFGFR4 in the HCT116 FUR and OXR cell lines. Equal loading was assessed by probing for actin
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Notably, apoptosis induced by FGFR4 depletion was found to
be FLIP-, caspase 8-, caspase 9- and Bax-dependent,
suggesting that FLIP downregulation following FGFR4
silencing leads to caspase 8 activation, which then cross-
talks with the mitochondria to promote Bax-mediated release
of cytochrome c and activation of caspase 9 followed by
activation of the executioner caspases 3 and 7.29
Recent data regarding FGFR1 in breast cancer has shown
that, following activation, the receptor is cleaved by the
protease Granzyme B and the C-terminus trafficks to the
nucleus, where it regulates cell migration.40 Interestingly, high
nuclear FGFR4 staining was found in our tumour CRC tissue,
and our phenotypic effects following FGFR4 inhibition could
be explained by a nuclear function of FGFR4 on STAT3 and
expression of c-FLIP. In addition, nuclear localisation of other
receptor tyrosine kinases, such as epidermal growth factor
receptor, has been correlated with a migratory phenotype and
poor prognosis.41–44
In summary, we have described a novel role for FGFR4 in
resistance to 5-FU and oxaliplatin chemotherapy in CRC.
Silencing of FGFR4 downregulates c-FLIP expression and,
in combination with chemotherapy, induces apoptosis in
parental and drug-resistant cell line models. The development
of selective small-molecule inhibitors will allow inhibition of
the FGFR4 to be explored as a potential therapeutic strategy
in CRC.
Materials and Methods
Materials. 5-FU, oxaliplatin and SN38 were purchased from Sigma Chemicals
(St. Louis, MO, USA), Sanofi-Synthelabo (Malvern, PA, USA) and Abatra
Technology (Xi’an, China), respectively. zVAD (OMe)-FMK was purchased from
Calbiochem (Darmstadt, Germany). BGJ398 was kindly provided by Novartis, and
all siRNAs were purchased from Qiagen (Crawley, UK).
Cell lines. Authentication and culture of CRC cell lines HCT116, LS174T and
RKO has been described previously.45 The HCT116 parental and HCT116 Bax /
isogenic human colon cancer cell lines were kindly provided by Professor Bert
Vogelstein (Johns Hopkins University, Baltimore, MD, USA) and maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM). The 5-FU-, oxaliplatin-, SN38-
resistant and c-FLIPL-overexpressing HCT116 sub-lines were generated as
previously described.30,31 The RKO and LS174T human CRC cell lines were
provided by the National Cancer Institute and the American Type Culture
Collection (ATCC), respectively, and maintained in DMEM.
CI values. siRNA transfection conditions have been previously described.45
CI values were calculated as previously described.46
Western blotting analysis. Western blots were performed as previously
described.47 PARP (eBioscience, San Diego, CA, USA), tSTAT3 (Cell Signalling
Technology Inc, Beverly, MA, USA), pERK (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), FLIP (NF-6) and Caspase 8 (Abexis Biochemical, Birmingham, UK) mouse
monoclonal antibodies were used in conjunction with a horseradish peroxidase-
conjugated sheep anti-mouse secondary antibody (Amersham, Chalfont St Giles, UK).
FGFR4 XP, pAKT, tAKT, Caspase 9, Bcl-2, Bcl-xl, Bax, XIAP (Cell Signalling
Technology Inc), FGFR4 C16, tERK, Mcl-1 (myeloid cell leukemia sequence 1; Santa
Cruz Biotechnology) and pSTAT3 (Abcam, Cambridge, UK) were used in conjunction
with anti-rabbit secondary antibody (Amersham). Equal loading was assessed using
GAPDH (glyceraldehyde-3-phosphate dehydrogenase; AbD Serotec, Oxford, UK).
Annexin V/propidium iodide (PI) analysis. Cells were harvested,
stained for Annexin V–fluoroscein isothiocyanate and PI uptake and analysed
using a BD FACSCalibur instrument according to the manufacturer’s instructions
(BD Biosciences, Oxford, UK). Levels of apoptosis were calculated as the sum of
the Annexin V positive/PI negative (early apoptosis) and Annexin V positive/PI
positive (late apoptosis) cell populations.
Caspase-activation assays. Caspase activity in cell protein isolates was
measured using Caspase Glo 3/7 and 8 assays (Promega, Madison, WI, USA).
Cell viability assays. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide) (Sigma Chemicals) assay was used to assess cell viability as
previously described.30
STAT3 reporter assay. The STAT3 reporter, negative and positive control
constructs were obtained from Qiagen (Crawley, UK) and transfected with FGFR4
or negative control siRNA using GeneJuice (Novagen, Darmstadt, Germany). The
Biotech Synergy 4 Multi-mode Luminometer and the Gen5 software programme
measured luminescence after 50ml of luciferase assay reagent was injected into
each well. Readings were taken after 1-s incubation (100–200 sensitivity) and
were recorded as relative luminescence units (RLU).
Immunohistochemistry. A human CRC TMA was obtained from the
Northern Ireland Biobank. The TMA was constructed using samples from patients
entered into a phase III randomised controlled trial of treatment with 5-FU/FA
chemotherapy versus observation alone following surgical resection of stage II and III
tumours.48 The trial was conducted in compliance with the Declaration of Helsinki and
ethical approval for this study was obtained from the local ethics committee. The TMA
consists of 1836 cores representing colon or rectal adenocarcinoma with matched
normal mucosa from 149 individuals (Supplementary Table S2).
Staining for FGFR4 (FGFR4 C16, Santa Cruz Biotechnology) was conducted
with the assistance of the Northern Ireland Molecular Pathology laboratory. The
TMA was scored by two independent observers, and for each core, two scores of
FGFR4 positivity were determined on the basis of plasma membrane/cytoplasmic
staining and nuclear staining. A semiquantitative scale of FGFR4 intensity was
assigned as an integer (0¼ no staining, 1¼mild, 2¼moderate, 3¼ strong
staining). In cases where there were replicate cores from a single tumour, an
average score was assigned. Nuclear staining was defined as negative for scores
r1 and positive if41. Fisher’s exact test was used to compare nuclear staining
scores between normal and tumour samples.
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